Pharmacokinetics of lisinopril in hypertensive patients with normal and impaired renal function.
The pharmacokinetics of lisinopril was studied after administration of single and multiple doses of 5 mg to hypertensive patients with normal and impaired renal function. In patients with severe renal failure the peak concentrations were higher, the decline in serum concentration was slower and the time to peak concentration was extended. Accumulation of lisinopril was highly correlated with the creatinine clearance. The effective half-life was doubled and tripled in patients with mild and severe renal impairment, respectively, as compared to patients with a normal renal function. Lisinopril lowered blood pressure in all three groups over 24 h. It is suggested that smaller doses of lisinopril should be administered to patients with severe renal failure.
van Schaik
B A
BA
Department of Nephrology, University Hospital, Utrecht, The Netherlands.
Geyskes
G G
GG
van der Wouw
P A
PA
van Rooij
H H
HH
Porsius
A J
AJ
D058186:Acute Kidney Injury / Q000097:blood* / Q000188:drug therapy; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D003404:Creatinine / Q000652:urine; D004334:Drug Administration Schedule; D004656:Enalapril / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use / Q000652:urine; D005260:Female; D005919:Glomerular Filtration Rate; D006207:Half-Life; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy / Q000652:urine; D007408:Intestinal Absorption; D017706:Lisinopril; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D004656:Enalapril; D003404:Creatinine; D017706:Lisinopril